For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Sales and marketing | - | - | 0 | |
| Research and development | 811,837 | 785,608 | 889,896 | |
| General and administrative | 1,126,994 | 831,339 | 1,095,465 | |
| Total operating expenses | 1,938,831 | 1,616,947 | 1,985,361 | |
| Operating loss | -1,938,831 | -1,616,947 | -1,985,361 | |
| Interest expense | - | 200 | 222 | |
| Interest income | 18,859 | 18,961 | 29,254 | |
| Other income, net | 731 | 554 | -275 | |
| Total other income, net | 19,590 | 19,315 | 28,757 | |
| Net loss | -1,919,241 | -1,597,632 | -1,956,604 | |
| Net loss applicable to common stockholders | - | -1,597,632 | - | |
| Basic EPS | -1.95 | -1.01 | -1.41 | |
| Diluted EPS | -1.95 | -1.01 | -1.41 | |
| Basic Average Shares | 984,668 | 1,574,535 | 1,387,118 | |
| Diluted Average Shares | 984,668 | 1,574,535 | 1,387,118 | |
Bluejay Diagnostics, Inc. (BJDX)
Bluejay Diagnostics, Inc. (BJDX)